Search for: rheumatoid arthritis methotrexate autoimmune disease biomarker gene expression GWAS HLA genes non-HLA genes
| ID | PMID | Title | PublicationDate | abstract |
|---|---|---|---|---|
| 3936165 | Lymphocyte activation in rheumatoid arthritis synovial fluid in vivo. | 1985 Nov | Monoclonal antibodies were used in avidin-biotin-peroxidase complex staining for activation marker analysis of rheumatoid synovial fluid cells. Although Ia expression indicates T cell activation, cells displaying receptors for interleukin 2 (Tac)-and transferrin receptor (T9)- positive proliferating cells were relatively few. Similarly, activated terminal effector cells of suppressor/cytotoxic nature were scarce in rheumatoid synovial fluid, as suggested by a low expression of Tac and 4F2 markers. The in vivo situation in the rheumatoid arthritic (RA) joint does not seem to be due to the inability of synovial fluid lymphocytes to become activated, because mitogen stimulation in vitro, in spite of a low proliferative response, induced expression of all the activation markers studied. The relevance of the present observations to the down-regulation of the active, inflammatory-immune response in situ is speculative, but the data show that in spite of T-cell activation and Ia expression, activated terminal effector cells of suppressor/cytotoxic nature are few in the RA joint in vivo. | |
| 3158122 | [Basic studies on enzyme therapy of immune complex diseases]. | 1985 Apr 12 | Several in vitro investigations and animal experiments are described which may be used as experimental basis for the enzymatic treatment of rheumatoid arthritis and, possibly, also other immune complex diseases. Demonstration of absorption of unaltered orally-administered radiolabelled enzymes is shown in guinea pigs and rabbits. In vitro experiments with 4 types of soluble immune complexes which were incubated with gradually increasing amounts of enzymes showed dose-dependent cleavage of complexes. Antigen-induced experimental arthritis of rabbits, fed different amounts of a therapeutically used mixture of enzymes at different times, could be inhibited by this treatment, in dependence of dosage and time of feeding. With respect to the therapeutic applications of this study, the results favour the use of a high dosage repeated daily administration, since duration of effect seems limited. | |
| 6354600 | Treatment of sleep disturbance in arthritis with chlormezanone. | 1983 | A double-blind, crossover study was carried out in 31 patients with rheumatoid arthritis or osteoarthritis who suffered from insomnia which was considered to be caused primarily by their disease. Patients received 7-day courses of 400 mg chlormezanone, 200 mg chlormezanone and placebo in a pre-determined random order. Patients rated chlormezanone significantly (p less than 0.025) more effective than placebo in overcoming sleep disturbance and preferred the 400 mg dose. There was also a trend towards better quality of sleep with chlormezanone, although this did not attain statistical significance in this relatively small study. Daytime alertness was similar for both active and placebo treatment periods. Chlormezanone, therefore, would seem to be a useful addition to antirheumatic therapy when there is related insomnia. | |
| 7183646 | Girdlestone arthroplasty. | 1982 Oct | A series of 92 patient who underwent excision arthroplasty of the hip (Girdlestone arthroplasty) as a primary procedure is presented. The operation was performed for various conditions which included femoral neck fracture, rheumatoid arthritis, ankylosing spondylitis, tuberculosis, septic arthritis, unreduced posterior dislocation of long duration, fracture of the acetabulum, avascular necrosis of femoral head and bony ankylosis. Excision of head and neck of the femur was found to be an excellent salvage procedure for infected hips especially yielding uniformly satisfactory results at all ages irrespective of the disease. It provided a painless, mobile hip. Except for shortening and unstable gait, no other handicap was observed; the disadvantages of this handicap were outweighed by its advantages, compared with the disadvantages of other sophisticated hip operations such as replacement, and mould arthroplasties or even total hip replacement. Our results were excellent in 21% of cases, good in 44% and fair in 26% while they were poor in 9%. In view of its functional end results, we feel that this measure can be a good alternative to more modern and sophisticated hip operations in the form of partial or total hip replacement under Indian conditions. | |
| 842145 | [Serum immunoglobulin patterns in rheumatoid arthritis]. | 1977 Jan | Immunoglobulins were estimated quantitatively in sera from patients with rheumatoid arthritis. According to the significantly increased immunoglobulin class(es), in RA patients as compared to normals the following immunoglobulin patterns were registered: IgG pattern, IgM pattern, IgA pattern, IgG-IgM-IgA pattern, IgG-IgM pattern and IgG-IgA pattern. The IgG-, IgA- and IgG-IgM-IgA patterns were predominantly found in sera from patients with seropositive RA. A positive correlation was found between other inflammatory parameters and high titered rheumatoid factor of the IgG-IgM-IgA-, IgG-IgA- and IgM patterns. C-reactive proteins were increased more frequently in seropositive cases and correlated quantitatively with the IgG-IgA-, IgG-IgM-, IgG-IgM-IgA and IgA patterns. Maximal erythrocyte sedimentation rates were accompanied with the IgG-IgA-, IgG-IgM-IgA- and IgG-IgM pattern. The serum complement components C 3 and C 4 were not decreased in neither seropositive nor seronegative RA. The formation of antiglobulins in hypergammaglobulinemic patients with RA induced by an increased immunoglobulin catabolism is suggested as a possible pathogenetic mechanism. | |
| 6398314 | Interim results on the clinical effects of i.v. administered thymopentin in active rheumat | 1984 | Forty-one patients with active rheumatoid arthritis entered a controlled, double-blind, randomized study; 21 received prolonged i.v. injections (10 min) of thymopentin 50 mg 3 times a week for 3 consecutive weeks; the other 20 received placebo under the same conditions. The groups were comparable at the start of the study. Statistical tests of changes within the treatment groups after 3 weeks showed that the improvement achieved in the thymopentin group was significant (p less than 0.05 or p less than 0.01) for each clinical parameter, except for left-hand grip strength. On the other hand, no significant improvement was observed for any parameter except morning stiffness in the patients on placebo. The intergroup comparison showed significant differences, favouring thymopentin over placebo treatment, in the Ritchie index, scores for swollen joints, assessment of severity of pain and scores for changes in the activity of the disease. Only minor side-effects were experienced in the two treatment groups. The present placebo-controlled double-blind study confirms the previous positive results achieved in open studies, i.e., the beneficial therapeutic effect of prolonged i.v. injections of thymopentin in patients with severe rheumatoid arthritis observed after 3 weeks of therapy. The drug appears to be safe at the dose regimen used. | |
| 7310771 | Uridine diphosphate glucose dehydrogenase in rheumatoid synovial cells in culture. | 1981 Sep | Extracts containing uridine diphosphate (UDP) glucose dehydrogenase (EC 1.1.1.22) activity were prepared from rheumatoid and from normal human synovial cell lines using previously standardized techniques. Although no significant differences in the enzyme from the 2 sources were detected with respect to activity, substrate affinities, or responses to temperature and pH, these determinations have demonstrated that the enzyme is very sensitive to alterations in these parameters. The ultimate activity of the enzyme in vivo will be dependent upon the extent of the increased temperature, acidity, and altered glucose metabolism in the rheumatoid joint. | |
| 786908 | Diclophenax sodium (Voltaren) in rheumatoid arthritis: a double-blind comparison with indo | 1976 Jun | Diclophenac sodium, Voltaren, has been tested against indomethacin and placebo in a four-week double-blind between-patient trial in 182 patients with rheumatoid arhritis. The ameliorating effect of Voltaren on the usual clinical parameters was comparable to that of indomethacin, while no significant changes were observed in the placebo group. Side effects during treatment with Voltaren and indomethacin appeared mainly form the gastrointestinal tract and from CNS. While side effects from the gastrointestinal tract were similar in the two groups, side effects from the CNS appeared significantly less frequent during treatment with Voltaren than during treatment with indomethacin. No skin reactions, diarrhoea or gastrointestinal bleeding were observed in either group. Long-term studies are needed to establish the place of Voltaren in the treatment of rheumatoid arthritis. | |
| 563238 | HLA-B27 frequency in Greek patients with acute anterior uveitis. | 1977 Nov | The histocompatibility antigen HLA-B27 was identified in 12 out of 33 patients with acute non-granulomatous anterior uveitis. This is a frequency of 36.36%, compared with 4.72% in controls. Seven patients had in addition evidence of systemic disease, including ankylosing spondylitis, sacroiliitis, Reiter's disease, Still's disease, and rheumatoid arthritis. Five of these were HLA-B27 positive, which suggests that the uveitis in many of these cases has a similar aetiology to the uveitis in those with rheumatic disease. It appears that the more severe cases of acute anterior uveitis are related more frequently to the presence of HLA-B27. | |
| 6085819 | Idiotype expression in rheumatoid synovial plasma cells. | 1984 | The majority of the polyclonal plasma cells identified in the synovial tissues of rheumatoid arthritis patients contain immunoglobulins that express a common idiotype related to that of the monoclonal cryoglobulins of the Wa group (RCRI). In these same tissues, there are twice as many plasma cells which are marked by a common idiotype yet do not show binding of aggregated IgG. These plasma cells are members of an idiotypically parallel set relative to those which produce rheumatoid factor. Direct comparison of rabbit polyclonal RCRI+ plasma cells with murine monoclonal RCRI+ plasma cells using two color fluorescent counterstains shows that the epitope recognized by the monoclonal anti-RCRI exists among a set of epitopes present in the RCRI. Since all the monoclonal RCRI+ plasma cells are not also positive with the polyclonal anti-RCRI antisera, the epitope characterized by the monoclonal antibody Glo 86.3 is not included among the set of epitopes the polyclonal antiserum identifies. A suitably absorbed anti-idiotypic polyclonal antiserum is superior to monoclonal antibodies for the purpose of detection of molecules (and cells) that are part of a polyclonal reaction involved in a given immune response. | |
| 6615562 | Leukapheresis in rheumatoid arthritis. Association of clinical improvement with reversal o | 1983 Sep | In order to study the clinical and immunologic effects of a brief course of leukapheresis, 14 patients with clinically similar rheumatoid arthritis were segregated into 2 subgroups. Group A (7 patients) had subnormal lymphocyte tritiated thymidine incorporation to soluble antigens. After a brief course of leukapheresis, 6 of these 7 patients demonstrated substantial clinical improvement associated with significantly enhanced lymphocyte tritiated thymidine incorporation to soluble antigens. In contrast, none of the 7 patients in group B (normal immune functions) demonstrated similar changes in articular indices or lymphocyte proliferation. Thus, clinical improvement induced in a subset of rheumatoid arthritis patients appears to reflect modulation of function, and not simply immunosuppression. | |
| 6440806 | Pulmonary gold toxicity. | 1984 Nov | A 52-year-old, white female developed low-grade fever, cough, and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis. The patient had severe hypoxemia associated with bilateral pulmonary infiltrates. Dramatic clinical improvement followed prednisone therapy. | |
| 6742907 | Haematuria in rheumatoid arthritis: an association with mesangial glomerulonephritis. | 1984 Jun | Twenty-four patients with rheumatoid arthritis and isolated haematuria were investigated for the cause of their haematuria. In 3 patients local urological disorders were identified, including a pelvicaliceal carcinoma. Renal biopsies were performed on the remaining 21 patients, and the most common abnormality found was a mild mesangial glomerulonephritis (71%). Immunofluorescence and electron microscopy in these patients usually gave normal results. The lesions occurred independently of gold or D-penicillamine therapy and were not associated with impairment of glomerular function. | |
| 6978206 | TG cells in peripheral blood lymphocytes from patients with rheumatoid arthritis. | 1981 Sep | Using combinations of methods for detecting Fc receptors and B lymphocytes, non-B, non-T lymphocytes and T lymphocytes we have shown T(G) cells to be significantly increased in rheumatoid arthritis (RA) patients' peripheral blood lymphocytes (PBL). The possible significance of this finding to the disease process is discussed. | |
| 7433927 | Plasma and synovial fluid pharmacokinetics and prostaglandin inhibitory effect of indoprof | 1980 | Indoprofen was given intravenously (bolus followed by infusion) and orally to 7 patients suffering from active rheumatoid arthritis with knee joint effusion. Indoprofen readily penetrated into synovial fluid in amounts which were directly correlated with areas under curves of plasma drug levels. Synovial fluid acted as a compartment distinct from the central (plasma) compartment. Indoprofen caused a substantial decrease in E2 and F2 alpha prostaglandin concentration in synovial fluid. | |
| 99093 | Immunodiffusion studies on synovial fluid from patients with rheumatoid arthritis: the rea | 1978 Aug | Synovial fluids (83.3%) from patients with rheumatoid arthritis gave a positive reaction when examined by immunodiffusion against a Lancefield extract of Group A Type 12 streptococci. None of the patients with osteoarthrosis reacted positively. An antiserum was prepared to the material in synovial fluid reacting with the streptococcal extract. This antiserum reacted positively with all synovial fluids tested including the osteoarthrosis patients. It also reacted with all plasma samples tested but only with a few (18.2%) of serum samples. Immunodiffusion and absorption experiments demonstrated that the material reacting with the streptococcal extract was fibrinogen. Of 12 other streptococci examined only one, a Group C organism, gave a similar positive reaction with synovial fluids. | |
| 6728445 | The carpometacarpal joints. | 1984 Apr | Although less complex than the intercarpal joints, the carpometacarpal joints are very important to proper hand function, and their derangement can be very disabling. The anatomy and clinical problems of these joints are covered in this article. | |
| 405017 | Acute myocardial infarction following gold sodium thiomalate induced vasomotor (nitritoid) | 1977 May | A vasomotor (nitritoid) reaction occurred following an initial injection of gold sodium thiomalate (GST; Myochrysine) in a 69-year-old man with rheumatoid arthritis (RA). An acute anterior wall myocardial infarction, documented by serial electrocardiographic and serum enzyme changes, developed immediately thereafter. A second patient, a 49-year-old man with RA and a history of GST-associated vasomotor reactions, was monitored clinically and electrocardiographically after GST administration. Sinus tachycardia developed and peripheral blood pressure fell within 2 minutes of injection, simultaneous with the onset of vasomotor symptoms. Vasomotor reactions from GST may compromise myocardial perfusion by their action on arteriolar smooth muscle, and thus result in peripheral vasodilatation, or they may act by adrenergic discharge initiated by such a reaction, and thus increase myocardial work and oxygen demand. Aurothioglucose (Solganal), rarely produces vasomotor reactions, and may be preferred to GST in elderly RA patients with concomitant cardiovascular disease or atherosclerosis. | |
| 6432416 | Longterm experience with oral gold in rheumatoid arthritis and psoriatic arthritis. | 1984 Mar | Oral gold (auranofin) has been used in 31 patients, 20 with active rheumatoid arthritis and 11 with active psoriatic arthritis. In rheumatoid arthritis the oral gold treatment was compared to parenteral gold treatment in a patient blind trial for two years. The psoriatic arthritis cases were incorporated in an open trial. Auranofin 6 mg once daily reduced significantly the activity in rheumatoid arthritis and in psoriatic arthritis. The beneficial effect obtained with auranofin at a dose of 6 mg/day during the first year of treatment could not be maintained by 3 mg/day in the second year. Auranofin compared to parenteral gold had a distinct advantage of better systemic tolerability, although parenteral gold was found to be more potent. There was no greater risk for toxic skin reaction to oral gold in psoriatic arthritis than in rheumatoid arthritis. The overall conclusion of this longterm study is that oral gold (auranofin) 6 mg once daily, although slightly less effective than parenteral gold, can be considered to be the first choice of gold treatment for rheumatoid arthritis and psoriatic arthritis, because the compliance, which is a reflection of a combination of tolerance and efficacy, for oral gold therapy was, in our hands, undoubtedly superior to parenteral gold. | |
| 812286 | [Animal experiments on the maintenance dose of D-penicillamine]. | 1975 Sep | The question of a D-penicillamine maintenance dose was tested by the load resulting in rupture of excised strips of dorsal skin of male albino rats. The reduction in load resulting in rupture (-48.5 per cent) obtained by 14 days of treatment with 320 mg/kg/day orally can be maintained completely over a treatment period of 28 days by daily administration of half the dose (160 mg/kg/day orally). Animal experimental findings correspond well with the procedure applied in hospital, to fix the maintenance dose at 30-50 per cent of the maximal dose after full effect is reached. |